Register for our free email digests:
Clovis Oncology Inc.
www.clovisoncology.com
Latest From Clovis Oncology Inc.
Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
AZ's Lynparza Gets Prostate Cancer Priority Review
The race is firmly on to be the first PARP inhibitor approved for metastatic castration-resistant prostate cancer, with the FDA giving a speedy review to AstraZeneca and Merck & Co's Lynparza just days after granting the same to Clovis Oncology's Rubraca.
New CEO At MorphoSys Seeking Partner For ‘CAR-T Killer’ Lymphoma Drug
Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.
Company Information
- Industry
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Clovis Oncology Inc.
- Senior Management
-
Patrick Mahaffy, Pres. & CEO
Dan Muehl, EVP, Fin.
Lindsey Rolfe, EVP, Clin. & Preclinical & Dev. & CMO - Contact Info
-
Clovis Oncology Inc.
Phone: (303) 625-5000
5500 Flatiron Parkway
Boulder, CO 80301
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice